Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Neurotech International ( (AU:NTI) ).
Neurotech International has reported a change in director Robert Maxwell Johnston’s interests following the expiry of 1,000,000 unlisted options held indirectly through Jondol Pty Ltd. The NTIOPT27 options, exercisable at $0.16 and expiring on 24 April 2026, lapsed without exercise, leaving Johnston’s indirect holding unchanged at 4,604,761 fully paid ordinary shares and no remaining options tied to this class.
The disclosure, lodged under ASX listing rules, indicates that the change in Johnston’s interests arose solely from the expiry of options rather than any on- or off-market trading activity. There was no associated consideration or alteration in contractual interests, suggesting limited immediate impact on Neurotech’s capital structure but providing shareholders with updated transparency on director equity exposure.
More about Neurotech International
Neurotech International Limited operates in the medical technology and neuroscience sector, focusing on neurological health solutions. The company is listed on the ASX and its securities include fully paid ordinary shares and various classes of options, reflecting an investor base attentive to director dealings and equity-based incentives.
Average Trading Volume: 1,456,144
Technical Sentiment Signal: Sell
Current Market Cap: A$17.13M
For an in-depth examination of NTI stock, go to TipRanks’ Overview page.